Investigational Drug Information for Netupitant
✉ Email this page to a colleague
What is the drug development status for Netupitant?
Netupitant is an investigational drug.
There have been 17 clinical trials for Netupitant.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2021.
The most common disease conditions in clinical trials are Vomiting, Nausea, and Breast Neoplasms. The leading clinical trial sponsors are Helsinn Healthcare SA, National Cancer Institute (NCI), and Parexel.
There are ninety US patents protecting this investigational drug and eight hundred and eighty-three international patents.
Summary for Netupitant
| US Patents | 90 |
| International Patents | 883 |
| US Patent Applications | 422 |
| WIPO Patent Applications | 334 |
| Japanese Patent Applications | 87 |
| Clinical Trial Progress | Phase 3 (2021-02-01) |
| Vendors | 84 |
Recent Clinical Trials for Netupitant
| Title | Sponsor | Phase |
|---|---|---|
| Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC | Guangxi Medical University | Phase 3 |
| Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) | Helsinn Healthcare SA | Phase 4 |
| Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer | Instituto Brasileiro de Controle do Cancer | Phase 2 |
Clinical Trial Summary for Netupitant
Top disease conditions for Netupitant
Top clinical trial sponsors for Netupitant
US Patents for Netupitant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Netupitant | ⤷ Try a Trial | Crystalline forms of fosnetupitant | Helsinn Healthcare SA (Lugano/Pazzallo, CH) | ⤷ Try a Trial |
| Netupitant | ⤷ Try a Trial | Cyclohexyl pyridine derivative | KISSEI PHARMACEUTICAL CO., LTD. (Matsumoto, Nagano, JP) | ⤷ Try a Trial |
| Netupitant | ⤷ Try a Trial | Method for cancer cell reprogramming | STC.UNM (Albuquerque, NM) | ⤷ Try a Trial |
| Netupitant | ⤷ Try a Trial | Estrogen-related receptor alpha based protac compounds and associated methods of use | Yale University (New Haven, CT) Arvinas, Inc. (New Haven, CT) | ⤷ Try a Trial |
| Netupitant | ⤷ Try a Trial | Curcuminoid formulations and related methods of treatment | DESIGNS FOR HEALTH, INC. (Suffield, CT) | ⤷ Try a Trial |
| Netupitant | ⤷ Try a Trial | Carboxymethyl piperidine derivative | KISSEI PHARMACEUTICAL CO., LTD. (Matsumoto-shi, Nagano, JP) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Netupitant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Netupitant | Australia | AU2016335060 | 2035-10-06 | ⤷ Try a Trial |
| Netupitant | Canada | CA2996466 | 2035-10-06 | ⤷ Try a Trial |
| Netupitant | China | CN108137626 | 2035-10-06 | ⤷ Try a Trial |
| Netupitant | European Patent Office | EP3359547 | 2035-10-06 | ⤷ Try a Trial |
| Netupitant | Japan | JP2018531249 | 2035-10-06 | ⤷ Try a Trial |
| Netupitant | Japan | JP6880009 | 2035-10-06 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
